Articles tagged with Prostate Cancer
A global study led by Johns Hopkins Medicine found that docetaxel therapy significantly improves survival time for hormone-resistant prostate cancer patients. Patients treated with tri-weekly docetaxel survived 2.4 months longer than those receiving the standard chemotherapy drug, mitoxantrone.
Two landmark studies show that Taxotere-based regimens improve patients' PSA responses by 43% and pain responses by 59%, leading to a 27% increase in disease-progression-free survival. The treatment also provides hope to thousands of men worldwide, offering an important new option for living longer.
A new study shows that estrogen skin patches can counteract high cholesterol associated with hormone therapy for prostate cancer. The patches decreased overall cholesterol levels by 10 percent and increased good cholesterol (HDL), while also improving lipid profiles.
Researchers found four distinct risk groups and seven independent risk factors for prostate cancer detection, including abnormal exam findings, age, family history, and PSA density. Men with high-risk features remain at risk despite multiple negative biopsies, emphasizing the need for vigilant follow-up.
A new study finds that estrogen therapy significantly improves verbal memory performance in men with advanced prostate cancer, while hormone deprivation impairs it. Estrogen also reduces depression and confusion in these patients.
A new study found that hormone deprivation therapy is less effective for younger men with higher grade tumors, suggesting it needs further investigation as an alternative treatment for localized prostate cancer. The study also revealed a higher risk of bone fractures in men on hormone therapy due to osteoporosis.
A new study suggests that men who take statins, common cholesterol-lowering drugs, have a significantly reduced risk of prostate cancer. Statin use was associated with a 58% lower risk of prostate cancer and a 55% lower risk of elevated PSA levels.
A new medication called atrasentan has shown promise in slowing the progression of prostate cancer to the bone, reducing pain and maintaining quality of life. The drug's effect on stabilizing disease progression was observed across phase II and III clinical trials.
Researchers explore alternative biomarkers for prostate cancer using immune responses to AMACR, while a new RNA interference strategy shows potential in silencing PLK1 genes. The latest AJCC breast cancer staging system revision also influences false-negative rates.
Researchers developed two treatments to minimize nerve damage and facilitate nerve recovery, preserving ability to have an erection after radical prostatectomy. Muscle-derived cells and glial cell-derived neurotrophic factors improved erectile function in animal models with cavernous nerve injury.
Researchers found that quality of life for men treated for prostate cancer continues to evolve long-term, with some experiencing improvements and others worsening. Sexual function remains a significant concern for survivors, with reported lower quality of life compared to non-cancerous individuals.
A study by Mount Sinai School of Medicine found that brachytherapy effectively treats prostate cancer while preserving quality of life. The research team followed 255 patients with prostate cancer treated with I-125 and reported minimal urinary symptoms, preserved potency, and reduced bleeding.
Researchers have identified a new biomarker, EPCA, which may enable early detection and treatment of prostate cancer. The study found that EPCA was expressed in tissue samples from patients with prostate cancer who initially had negative biopsies.
Researchers found a significant association between high blood testosterone levels and an increased risk of prostate cancer in older men. The study, which followed over 3,000 men for 40 years, also showed that the protein sex hormone-binding globulin (SHBG) was associated with a slightly decreased risk for prostate cancer.
A UMHS study found that African-American men with a history of gonorrhea are more likely to develop prostate cancer. The research suggests an inflammatory effect from the bacterial infection may trigger pre-existing cancerous cells to multiply, increasing risk.
Moderately and severely obese patients experienced higher Gleason scores and rising PSA levels after surgery, indicating aggressive prostate cancer. Men with a BMI of greater than 35 kg/m2 had a 60% risk of cancer recurrence within three years.
A study found that over half of men taking part in a prostate cancer risk assessment program reported using dietary supplements to prevent the disease. The most commonly used supplements were vitamins and minerals, with saw-palmetto being one popular option.
A University of Michigan study found that most prostate cancer treatment guides overlook key details and favor active treatment over watchful waiting. The researchers recommend complete information on risks and benefits, clear writing styles, and visual elements to engage readers.
A study confirmed that BRCA2 mutations are linked to prostate cancer, with a risk 4.8 times higher than in healthy individuals. The results suggest that prostate cancer screening may begin at age 50 for men carrying these mutations.
A study found that black men with prostate cancer are more likely to die from the disease due to delayed or inadequate care, particularly those without other diagnosed illnesses. The researchers suggest that cultural and social factors contribute to this disparity.
A study found that men who consumed green and black tea for five days had slower-growing prostate cancer cells compared to those who drank diet or regular soda. The researchers discovered a significant negative correlation between total polyamine levels and tea polyphenol content in the tissue.
A new online tool provides personalized 10-year survival predictions for prostate cancer patients, taking into account age, race, co-morbidities, and treatment type. The model also highlights the significant impact of co-morbidities on long-term survival rates.
Prostate cancer cell lines exhibit high levels of free radical damage and defective repair mechanisms, leading to a cascade of events culminating in further DNA damage and cellular dysfunction. The new research provides solid evidence for the critical role of free radicals and repair in prostate cancer development.
A large cohort study found no association between ejaculation frequency and increased prostate cancer risk. High ejaculation frequency may actually be associated with a lower risk of total and organ-confined prostate cancer.
Researchers found that men with a family history of prostate cancer can accurately assess their lifetime risk and are more likely to use supplements to improve their health. The study also reveals that younger brothers of men with prostate cancer are nearly four times more likely to report using complementary or alternative medicine.
A study found that equol, a natural metabolite from soy isoflavones, blocks the effects of DHT without altering testosterone levels, reducing prostate size in rats. This molecule may offer a treatment for BPH and prostate cancer, as well as promoting healthy skin and hair growth.
A recent UMHS study found that black men with moderate-grade prostate cancer are 36% less likely to receive treatment than white men. Hispanic men also face disparities in treatment, with 16% fewer chances of receiving definitive therapy compared to white men.
A team of scientists at Rutgers University has identified the active compound in croton plant oil, TPA, which shows promise in treating prostate cancer. The study found that TPA can stop new cells from growing, kill existing cancer cells, and shrink prostate tumors.
A study of 501 patients with recurrent prostate cancer found that salvage radiotherapy can be effective for patients with high-grade disease and rapid PSA doubling time, suggesting it may prevent metastatic disease progression. The study's findings support early treatment for these patients, who are at the highest risk of disease spread.
Researchers have developed a gene expression profiling method that predicts clinical outcome in prostate cancer patients. The study's findings suggest that this approach can improve our ability to stratify patient populations and optimize disease treatment.
A new biomarker, EPCA, has been discovered that can detect prostate cancer earlier than traditional methods. The marker is expressed in the tumor and throughout the prostate in men with prostate cancer.
The new guidelines recommend limiting treatment to patients at expected risk for metastatic disease and only evaluating drugs with demonstrated clinical activity. The guidelines also require significant proportion of patients to show decline or no increase in PSA and prostate-cancer specific survival.
A comprehensive review of 72 studies found no evidence that testosterone replacement therapy increases prostate cancer or cardiovascular disease risk. Testosterone therapy may alleviate symptoms of low testosterone levels, but monitoring is crucial due to potential side effects.
Two studies found obesity increases risk of aggressive prostate cancer and cancer recurrence in African-American men. Obesity is associated with higher Gleason scores and elevated PSA levels, suggesting a link between excess body fat and tumor growth.
A study led by Rutgers University professor Mohamed Rafi founds a compound called ß-hydroxy-DHP (BHP) in licorice root supplements that can stop the growth of prostate and breast cancer cells. This could provide new hope for more effective therapies against these leading cancers.
Researchers are investigating the role of broccoli-derived chemicals in preventing prostate cancer. The study aims to better understand how these substances inhibit prostate cancer growth and identify potential biomarkers for future intervention trials.
A new study finds that older men with healthy life expectancy are less likely to receive adequate cancer treatment than younger patients. Despite better prognosis, older prostate cancer patients may not receive important treatments that could extend their life.
A study found that 29.8% of Ontario men diagnosed with prostate cancer used complementary medicine, highlighting the need for awareness and discussion among clinicians. The most commonly used products were natural health supplements like vitamin E, saw palmetto, and selenium, which may interact with conventional therapies.
Researchers found that c-myc promotes androgen-independent growth in prostate cancer cells, slowing growth with downregulation. This suggests a physiological role for c-myc in prostate cancer and offers a possible therapeutic target.
A study of 33 elderly men with advanced prostate cancer found that external beam radiation therapy was well-tolerated and effective in keeping the cancer at bay. The patients experienced no unusual interruptions in treatment due to illness from radiation, and many remained alive and disease-free for several years.
Researchers found that black patients undergoing surgery had a median survival time 1.8 years less than white patients, with disparities smaller among radiation therapy and non-aggressive therapy groups. The study suggests genetic and environmental factors may contribute to these racial disparities in prostate cancer treatment outcomes.
A new campaign, SELECT Sunday, aims to raise awareness of prostate cancer among African-American men, who have the highest incidence rates and a death rate more than double that of white men. The campaign seeks to double African-American enrollment in an international study investigating vitamin E and selenium as preventive measures.
A study published in the Journal of the National Cancer Institute found that rats fed whole tomato powder had a 26% lower risk of prostate cancer death compared to those on control diets. The researchers suggest that whole tomato products and energy balance may offer independent benefits against prostate cancer.
A recent study suggests that lycopene's anti-cancer effect is enhanced by other compounds in tomatoes, such as phytochemicals. Whole tomato consumption was found to offer a lower risk of prostate cancer death compared to dietary supplements.
Researchers at Ohio State University Comprehensive Cancer Center found that a diet rich in whole tomatoes, but not supplements, was associated with longer survival rates and reduced risk of prostate cancer. The study also showed that energy restriction did not offer additional benefits over a balanced diet.
Researchers will study the biology of tumor-stroma interaction, heparan sulfate proteoglycans in bone metastasis, and mitochondrial DNA mutations to develop novel diagnostic and therapeutic strategies. The goal is to understand how prostate cancer cells metastasize to bone and discover new genes that may support or inhibit this process.
Research studies reveal that weight loss, exercise, and dietary changes can lower breast cancer risk by up to five percent of body weight and increase physical activity levels associated with reduced mammographic breast density. Additionally, a low-carbohydrate diet may be more effective in preventing prostate cancer progression.
Researchers found correlations between cellular features and cancer development in prostate and ovarian cancers. Prostatic intraepithelial neoplasia may be a significant target for prevention strategies.
Scientists at Memorial Sloan-Kettering Cancer Center discovered that the amount of PTEN protein produced affects prostate cancer progression. Mouse models showed varying levels of PTEN protein led to aggressive or benign tumors, suggesting novel clinical strategies for diagnosis, treatment, and prevention.
Researchers created mouse models to study PTEN's impact on prostate cancer progression. Subtle reductions in PTEN dose produced progressive changes in the biology of tumors, with mice having no functional PTEN genes showing the most invasive and aggressive cancers.
A study by Pollack and colleagues finds that a high Ki-67 biomarker is linked to increased risk of distant metastasis and death in prostate cancer patients. The researchers also suggest that Ki-67 can help identify high-risk patients who may benefit from alternative treatment strategies.
High doses of radiation therapy directed at the prostate significantly impact cancer control in high-risk patients. The major site of treatment failure is the prostate, highlighting the importance of high doses in this group.
Researchers discovered a genetic link between prostate cancer and a specific gene variant, CYPIBI. The study found that tiny variations in the gene may increase or decrease its cancer-causing effects, leading to a higher risk of developing prostate cancer.
Researchers at Penn aim to understand factors influencing poor prostate cancer outcomes among African-American men, including biological, environmental, and behavioral aspects. The study's findings may help develop better tools for prevention and treatment, ultimately improving clinical outcomes for this underserved population.
A recent study found that men aged 55-74 who received regular prostate cancer screenings every 4 years had a low rate of interval cancers. The screening procedure showed an 85.5% high sensitivity rate for detecting cancers, suggesting that very few aggressive prostate cancers escape screening.
Researchers have created a new method that could detect diseases at earlier stages than possible now, using protein targets like PSA. The method is a million times more sensitive than conventional methods and has the potential to revolutionize cancer diagnostics and treatment.
Prostate cancer mortality rates are falling fast in the US and Europe due to earlier diagnosis and hormonal treatments. Research shows that prompt surgery and hormonal therapy can improve 10-year survival rates for both prostate and breast cancers.
A systematic review and meta-analysis found that men with a family history of prostate cancer have an increased risk of developing the disease. The study revealed a 2.9 fold increased risk when the affected relative was a brother, highlighting the importance of identifying at-risk populations for targeted screening.
A clinical trial found that oral sodium clodronate reduced the risk of symptomatic bone progression by 21% and mortality by 20% compared to placebo, but with limited statistically significant results due to small population size. However, side effects were common, particularly in older patients.
A new nomogram model predicts prostate cancer likelihood in men with PSA levels below 10 ng/ml, helping to reduce unnecessary biopsies. The model identifies four independent risk factors for positive biopsy results and provides a score to calculate the likelihood of cancer presence.